CAS: 1702967-37-0
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | PSMA-617 REF: IN-DA01EO3MCAS: 1702967-37-0 | 99% | To inquire | Tue 10 Dec 24 |
 | Vipivotide tetraxetan REF: TM-T12573CAS: 1702967-37-0 | 100% - 98.45% | 180.00 €~1,826.00 € | Tue 17 Dec 24 |
 | PSMA-617 REF: 3D-CTC96737CAS: 1702967-37-0 | Min. 95% | 256.00 €~1,276.00 € | Thu 19 Dec 24 |
 | PSMA-617 REF: TR-P143100CAS: 1702967-37-0 | - - - | 15,186.00 € | Tue 21 Jan 25 |
PSMA-617
CAS:1702967-37-0
Formula:
C49H71N9O16
Purity:
99%
Color and Shape:
Solid
Molecular weight:
1042.1387
Ref: IN-DA01EO3M
| 1mg | 121.00 € | ||
| 5mg | 263.00 € | ||
| 10mg | 573.00 € | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 10 Dec 2024
Vipivotide tetraxetan
CAS:1702967-37-0
Vipivotide tetraxetan (PSMA-617) is a high potent inhibitor of prostate-specific membrane antigen (PSMA)(Ki of 0.37 …
Formula:
C49H71N9O16
Purity:
100% - 98.45%
Color and Shape:
Solid
Molecular weight:
1042.14
Ref: TM-T12573
| 1mg | 180.00 € | ||
| 2mg | 268.00 € | ||
| 5mg | 450.00 € | ||
| 10mg | 645.00 € | ||
| 25mg | 1,006.00 € | ||
| 50mg | 1,391.00 € | ||
| 100mg | 1,826.00 € | ||
| 1mL*10mM (DMSO) | 1,123.00 € |
Estimated delivery in United States, on Tuesday 17 Dec 2024
PSMA-617
CAS:1702967-37-0
Vipivotide tetraxetan (PSMA-617) contains three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA (DOTA) which is …
Formula:
C49H71N9O16
Purity:
Min. 95%
Color and Shape:
Powder
Molecular weight:
1,042.14 g/mol
Ref: 3D-CTC96737
| 1mg | 256.00 € | ||
| 2mg | 400.00 € | ||
| 5mg | 711.00 € | ||
| 10mg | 1,021.00 € | ||
| 25mg | 1,276.00 € |
Estimated delivery in United States, on Thursday 19 Dec 2024
PSMA-617
Controlled ProductCAS:1702967-37-0
Formula:
C49H71N9O16
Color and Shape:
Neat
Molecular weight:
1042.139
Ref: TR-P143100
| 100mg | 15,186.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
